A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

NCT03499899 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: LAG525
DRUG: PDR001
DRUG: Carboplatin

Sponsor

Novartis Pharmaceuticals